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Octreotide may extend survival in hepatocellular carcinoma (HCC). Forty-one per cent of HCCs have high-affinity somatostatin
receptors. We aimed to determine the feasibility, safety, and activity of long-acting octreotide in advanced HCC; to identify the best
method for assessing somatostatin receptor expression; to relate receptor expression to clinical outcomes; and to evaluate toxicity.
Sixty-three patients with advanced HCC received intramuscular long-acting octreotide 20mg monthly until progression or toxicity.
Median age was 67 years (range 28–81 years), male 81%, Child–Pugh A 83%, and B 17%. The aetiologies of chronic liver disease
were alcohol (22%), viral hepatitis (44%), and haemochromatosis (6%). Prior treatments for HCC included surgery (8%),
chemotherapy (2%), local ablation (11%), and chemoembolisation (6%). One patient had an objective partial tumour response (2%,
95% CI 0–9%). Serum alpha-fetoprotein levels decreased more than 50% in four (6%). Median survival was 8 months. Thirty four of
61 patients (56%) had receptor expression detected by scintigraphy; no clear relationship with clinical outcomes was identified. There
were few grade 3 or 4 toxicities: hyperglycaemia (8%), hypoglycaemia (2%), diarrhoea (5%), and anorexia (2%). Patients reported
improvements in some symptoms, but no major changes in quality of life were detected. Long-acting octreotide is safe in advanced
HCC. We found little evidence of anticancer activity. A definitive randomised trial would identify whether patients benefit from this
treatment in other ways.
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Hepatocellular carcinoma (HCC) is a major cause of cancer death
and morbidity worldwide (Johnson, 1996) It is frequently
complicated by pre-existing chronic liver disease, limiting
therapeutic options. While early disease can be managed by
resection or local ablation, decreased hepatic reserve may limit the
options for surgery or systemic therapy. Furthermore, response
rates for systemic therapy are low: no single agent has a response
rate higher than approximately 20%, and none improves survival
(Leung and Johnson, 2001). Multiagent therapy using cis-platinum,
doxorubicin, 5-fluorouracil, or interferon-alpha may show higher
response rates (Leung et al, 1999). However, because patients with
HCC frequently have advanced liver disease and associated
comorbidities, they are often unable to tolerate intensive and
toxic treatment. On the basis that some HCCs have hormone
receptors, hormonal approaches (including tamoxifen in a variety
of doses) have been evaluated; however, none of these has shown a
survival advantage over best supportive care (Chow et al, 2002).
A small randomised trial conducted by Kouroumalis et al (1998)
suggested that survival was longer in a group treated with short-
acting octreotide than in an untreated control group (median
survival 13 vs 4 months, 12-month survival 56 vs 13%, P¼0.002).
High-affinity somatostatin receptors capable of binding octreotide
are present in approximately 40% of HCC, and not in adjacent
liver. However, the numbers of high-affinity receptors are lower
than reported for neuroendocrine tumours (Reubi et al, 1999).
Somatostatin is a potent inhibitor of several growth factors and
angioneogenesis (Florio et al, 2003); it also has immune-
modulating properties (Lambrecht, 2001). Neuroendocrine and
epithelial tumour cell growth can be inhibited in vitro and in vivo
by the semisynthetic somatostatin analogue, octreotide (Lamberts
et al, 1990). The long-acting depot form of octreotide (sandostatin
long-acting release (LAR)) is formulated in microspheres, enabling
treatment to be delivered by monthly intramuscular (i.m.)
injection. It is currently used for the treatment of acromegaly
(Freda, 2002) and functional neuroendocrine tumours (de Herder
and Lamberts, 2002). Little information is available about its
elimination kinetics in cirrhosis, although the short-acting form
has been studied (Jenkins et al, 1998).
In patients with portal hypertension, octreotide has been used
extensively in the management of acute variceal bleeding and other
complications, where it reduces portal blood pressure in patients
with poor liver function (Jenkins et al, 1997). Although the benefit
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sobserved by Kouroumalis et al (1998) may be a direct anticancer
effect mediated by specific receptors on HCC cells, its effects on
portal hypertension may also reduce the frequency of variceal
bleeding. Octreotide therefore has the potential to affect survival
by more than one mechanism.
We undertook a clinical trial to evaluate octreotide LAR in
patients with unresectable HCC. The aims of this study were to
assess the feasibility, safety, and activity of octreotide LAR in
patients with advanced HCC before considering a definitive
randomised phase III trial. Because clinical outcomes could
potentially depend on somatostatin receptor status, we sought to
evaluate the relationship between somatostatin receptor expres-
sion, objective response rate, and survival. The utility of
noninvasive scanning as a predictor of response was examined
by correlating octreotide scintigraphic scanning and biopsy data
with survival. Receptor expression was evaluated by immuno-
histochemistry (IHC) and external scanning using labelled ligand
(octreoscan). Since the study population was largely composed of
people with impaired liver function and portal hypertension,
plasma pharmacokinetic studies were also performed to assist in
the overall assessment of the feasibility of using octreotide LAR in
these patients.
PATIENTS AND METHODS
All patients had unresectable HCC, diagnosed either by histology
or by the combination of typical findings on imaging and alpha-
fetoprotein level (AFP) 4500IUml
 1. World Health Organisation
performance status was 0–2 and no previous treatment with
octreotide for HCC was permitted. Exclusion criteria included
white blood count o2.0 10
9l
 1, platelets o50 10
9l
 1, haemo-
globin o10.0gl
 1, serum creatinine 40.15mmoll
 1, bilirubin
450moll
 1, albumin o25gl
 1, and AST and ALT 45 times the
upper limit of normal. Patients were also excluded if the
prothrombin ratio (INR) was 42.0, if they were receiving
concurrent antitumour treatment for HCC, or if they had
uncontrolled ascites requiring paracentesis within 4 weeks,
variceal bleeding in the previous month, prior radiation therapy
to the only evaluable site of disease, or Child–Pugh class C
cirrhosis. All patients gave informed consent and the protocol was
approved by the institutional review board of each participating
institution.
Treatment consisted of octreotide LAR 20mg by deep i.m.
injection every 28 days. The planned duration of treatment was
12 months in the absence of disease progression, unacceptable
toxicity, or withdrawal at the patient’s or doctor’s discretion. An
extension phase allowed treatment to continue beyond 12 months
on an individual basis at the discretion of the principal
investigator.
Before starting treatment, all subjects had a complete medical
history and physical examination, chest X-ray, and imaging to fully
define the extent of disease. Triple-phase spiral computed
tomography (CT) was recommended for imaging the liver. Blood
tests included full blood count, tests of liver function (serum
albumin, alkaline phosphatase, total bilirubin, AST, and ALT),
coagulation (INR and APTT), blood sugar, AFP, and tests to
evaluate the aetiology of liver disease (HBsAg and anti-HCV).
Blood was also sampled for octreotide pharmacokinetics and
assessment of chromogranin A levels before the 4th and 7th doses.
All patients had an octreotide scintigraphy scan before commen-
cing treatment.
Tumour biopsy for receptor analysis was optional, depending on
the availability of suitable tissue. Where available, archival
material was assessed for receptor expression by IHC at a central
laboratory.
Subjects were seen monthly for clinical review, blood tests, and
administration of the study drug. Response was assessed using the
RECIST (response evaluation criteria in solid tumours) criteria
(Therasse et al, 2000). Radiological assessment was undertaken 3-
monthly and any partial or complete responses were confirmed 1
month later.
Health-related quality of life (HRQL) was self-rated by patients
each month before their clinical review using two instruments: the
FACT-Hep (Heffernan et al, 2002) and the ‘Patient Disease And
Treatment Assessment’ form (Pt DATA Form). After the first
month of treatment, patients also rated how aspects of their HRQL
had changed, using a series of transition scales referred to here as
the subjective Patient Benefit Form. We decided a priori to focus
on changes in HRQL at 1 month because the number of evaluable
patients was expected to fall quickly from then on.
The FACT-Hep (Heffernan et al, 2002) is a validated 45-item
self-rated questionnaire, incorporating the FACT-G questionnaire
(27 items) (Cella et al, 1993), which covers multiple general aspects
of HRQL, and an 18-item module specific for hepatobiliary cancer.
Scores are calculated for four domains from the FACT-G: physical,
social–family, emotional, and functional well-being. In addition, a
total score including the hepatobiliary-specific items is calculated
(Cella, 1997).
The Patient DATA Form is a simple, pragmatic, patient-rated
instrument designed to measure aspects of HRQL that are relevant
to people with advanced cancer. Its development is reported
elsewhere (Nowak et al, manuscript in preparation). It assesses 24
aspects of HRQL using simply worded items listed on a single
page: 16 physical and emotional symptoms of cancer rated on a
numeric scale from 0 (no trouble at all) to 10 (worst I can imagine)
and eight aspects of well-being rated from 0 (worst possible) to 10
(best possible) (Appendix A).
The Patient DATA Form is designed to be rapidly and easily
interpreted: there is no scoring or aggregation procedure. Items
are arranged in two blocks: symptoms and dysfunctions (0 on left,
10 on right) where high scores reflect worse quality of life or more
severe symptoms; and aspects of well-being (10 on left, 0 on right)
where high scores reflect better well-being and quality of life.
Troublesome aspects stand out by being circled on the right side of
the page.
The Patient Benefit Form is a health-transition scale that rates
changes in the same aspects assessed with the Patient DATA Form
using a similar simple, one-page format. Patients rated how each
symptom or function has changed since their first injection 4
weeks previously using a five-point Likert scale: much better, a
little better, the same, a little worse, or much worse.
Pharmacokinetics
Samples were taken immediately before the 4th and 7th doses of
octreotide (weeks 12 and 24 of treatment). These time points were
selected in order to assess trough octreotide plasma concentrations
at steady state after three doses and to determine potential
octreotide accumulation in this cirrhotic population with more
continued dosing. Additional samples were also collected in some
cases. Plasma octreotide levels were determined by radioimmuno-
assay kindly performed by M Rouilly (Novartis Pharma AG,
Basel, Switzerland). The lower limit of quantification was
50pgml
 1 for a 50ml plasma sample.
Octreotide scintigraphy
111In-pentetreotide, 130–220MBq, was administered intrave-
nously. Images were acquired at all study sites with a standardised
imaging protocol. All images were acquired on dual-headed
gamma cameras using medium-energy parallel-hole collimators.
Anterior and posterior planar images (15minimage
 1) were
acquired over the abdomen and at other sites of known disease
24h after injection. Additional whole-body or SPECT images were
acquired after 4 or 24h in some patients.
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images, blinded to each other’s interpretation. Tracer uptake in the
primary tumour and metastases was determined relative to normal
liver. Abdominal CT scan reports were used for tumour
localisation. Uptake at the tumour site was scored as negative,
clear but faint, moderate, or intense. Disagreement between
reviewers was resolved by consensus.
Immunopathology
Archival paraffin-embedded tissue was stained for somatostatin
receptor, type SSTR2A, using rabbit polyclonal antiserum SS800
(Jomar Diagnostics, Adelaide, Australia) raised against amino-acid
sequences 355–369 (ETQRTLLNGDLQTSI) of human, rat, and
mouse SSTR2A receptor coupled to KLH. This antibody recognises
the C-terminus of human, rat, and mouse SSTR2A receptor.
Specificity of antibody binding was determined by blocking with
cognate peptide. Positive control staining was determined using
normal pancreas, islet cell, and other neuroendocrine tumours,
where cytoplasmic and membrane staining of normal pancreatic
islets was observed. Three-micron sections were pretreated with
10mM sodium citrate, pH 6.0, for 2min. Endogenous peroxidase
was blocked with 3% hydrogen peroxide for 10min. Antiserum
was applied at 1:2000 in 50mM Tris-HCl, pH 7.6, 0.05% for 30min
at room temperature. Chromogen was DAB (DakoCytomation,
Sydney, Australia).
Chromogranin A
Plasma chromogranin A levels were measured to see whether this
marker of neuroendocrine differentiation provided a useful
correlation with receptor expression, thereby serving as a simple
blood test for receptor-bearing tumours. The levels were assayed
by Network Pathology (Melbourne, Australia), using the Chromo-
granin A ELISA kit (DakoCytomation, Sydney, Australia).
Statistical methods
The sample size of 63 was designed to give 480% power to detect
an 8-month difference in median survival comparing the 40%
patients expected to have a positive octreoscan vs the remainder
expected to have a negative octreoscan (estimated survivals 12 and
4 months, respectively, as per the treatment and control arms in
the Kouroumalis study). Survival times were calculated from the
day of registration. Survival curves were calculated using the
method of Kaplan–Meier. The log-rank test was use to compare
the relationship between receptor expression by scintigraphy and
survival duration. Proportions were compared using w
2 tests.
Quality-of-life results were described and analysed with simple
descriptive and comparative methods. For each item in the Patient
Benefit Form, we recorded the proportions of patients reporting
that each aspect was much better, a little better, the same, a little
worse, or much worse than before starting treatment, and used w
2
tests to compare the proportions of patients who reported feeling
better vs those who reported feeling worse. For the Patient DATA
Form and FACT-Hep, we used Wilcoxon’s rank-sum tests for
paired data to compare baseline and 1-month scores for each
domain. Responses from the Patient Benefit Form were compared
with change scores from the Patient DATA Form using Spearman’s
rank-correlation coefficient.
RESULTS
The study accrued 63 patients with otherwise untreatable HCC
between April 2001 and January 2002. Study sites are listed in
Appendix A. The patients’ baseline characteristics are shown in
Table 1. The median age was 67 years (range 28–81 years) and
most of them were male. Most had good performance status.
Eleven had Child–Pugh class B cirrhosis and 52 had well-
compensated disease (Child–Pugh class A). Viral hepatitis was
the main cause of cirrhosis, with 28 patients (44%) having evidence
of hepatitis B or C infection. A small number of patients had
cirrhosis from other causes. Approximately half had received other
treatment for HCC.
Administration of treatment
Four patients (6%) did not receive any octreotide because their
disease progressed so rapidly they were unable to start treatment.
These patients were not eligible for analysis of response or toxicity,
but are included in the survival analysis. Three patients (5%)
received one dose, 12 (19%) two doses, 10 (16%) three doses, 10
(16%) four doses, seven (11%) five doses, four (6%) six doses, five
(8%) seven doses, and seven (18%) eight doses or more. The main
reason for stopping treatment was disease progression in 19
patients (30%). A further five patients (8%) withdrew and nine
(14%) died during treatment, all from progressive disease.
Treatment was stopped because of adverse effects (cramps) in
only one case.
Table 1 Patient characteristics
Characteristic n %
Sex
Male 51 81
Female 12 19
WHO performance status
02 0 3 2
13 0 4 8
21 3 2 1
Cirrhosis: Child–Pugh class
A5 2 8 3
B1 1 1 7
Raised AFP 50 79
Race
Caucasian 40 63
Asian 14 22
African 1 2
Polynesian or Melanesian 4 6
Other 4 6
Possible causes of HCC
a
Alcoholic liver disease 14 22
Hepatitis 40 63
HBsAg and no antibody to HCV 16 25
Antibody to HCV and no HBsAg 9 14
HBsAg and antibody to HCV 3 5
No HBsAg or antibody to HCV 6 10
Unclassified 6 10
Haemochromatosis 4 6
Other 7 11
Most recent treatment for HCC
No previous therapy 31 49
Surgery 5 8
Chemotherapy 1 2
Local ablation 7 11
Chemoembolisation 4 6
Other 15 24
HBsAg¼hepatitis B surface antigen; HCC¼hepatocellular carcinoma; HCV¼
hepatitis C virus; WHO¼World Health Organisation.
aSome patients had several
causes.
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Objective tumour response data for all 63 patients are summarised
in Table 2. Reductions in AFP were accompanied by imaging
evidence of partial response in one patient (2%, 95% CI 0–9%),
stable disease in one patient, and progressive disease in two
patients.
Survival
Survival status is shown in Table 3 and Figure 1. After a median
follow-up of 12 months, the median survival was 8 months (range
1–25 months), and five patients remain on treatment 21–25
months after starting. There was no statistically significant
relationship between receptor expression by octreotide scintigra-
phy and survival duration (P¼0.33) (Figure 2).
Treatment was well tolerated. Table 4 shows the main toxicities,
including diarrhoea, abdominal cramping, and alterations in blood
sugar (chiefly hyperglycaemia). Most toxicities were grade 1 or 2;
the only grade 3 or 4 toxicities were diarrhoea, alterations in blood
sugar, and anorexia. Diarrhoea is a common symptom in patients
with advanced HCC even in the absence of any treatment.
Adverse events
Most of the adverse events were attributable to chronic liver
disease and its complications (Table 5). All deaths were
attributable to progressive HCC. Two adverse events had unrelated
causes (incarcerated inguinal hernia and an abscess).
Gastrointestinal bleeding
With a total follow-up approaching 4000 patient-months, gastro-
intestinal bleeding occurred in four of 63 patients. In one patient,
this was from peptic ulcer disease and in the others was from
varices.
Table 2 Tumour responses
Best response n %
Tumour response (RECIST)
Complete response 0 0
Partial response
a 12
Stable disease 15 24
Progressive disease 23 37
Unknown 9 13
Not available 15 24
Total assessable 63 100
AFP response
a,b
450% reduction
c 47
450% reduction and no progressive disease
c 23
Total assessed 59 100
AFP¼alpha-fetoprotein; RECIST¼response evaluation criteria in solid tumours.
aConfirmed on two consecutive assessments at least 4 weeks apart.
bBaseline AFP
level needed to be more twice the upper limit of normal to qualify as a response.
cThese two AFP responses without progressive disease are also counted in the row
above.
Table 3 Survival status at March 2003
Patient status n %
Dead (tumour progression) 48 76
Dead (other causes)
a 23
Alive, still on study treatment 5 8
Alive, not on study treatment 8 12
Total 63 100
aOne, pneumonia; one, sepsis.
Overall survival
Number at risk
01 2 9 6 31 5 1 8
Months from registration
0
0.2
0.4
0.6
0.8
1
Median: 8
months
63 51 34 24 10 3
Figure 1 Overall survival.
Table 4 Toxicity: numbers of patients with each grade as their most
severe during their course of treatment
Toxicity grade (NCI)
a
Type of toxicity 0
b 1 2 3 4 % with grade 3 or 4
Diarrhoea 28 22 10 3 0 5
Abdominal cramping 47 9 7 0 0 0
Hyperglycaemia 45 4 9 5 0 8
Hypoglycaemia 60 2 0 0 1 2
Bruising 60 3 0 0 0 0
Alopecia 62 1 0 0 0 0
Pancreatitis 63 0 0 0 0 0
Anorexia 40 14 8 1 0 2
Other 63 0 0 0 0 0
aNCI Common Toxicity Criteria Version 2.
bGrade 0¼no toxicity.
0.6 1 1.4 1.8 2.2 2.6
0 3 6 9 12 15
Months from registration
0
0.2
0.4
0.6
0.8
1
Survival by baseline octreoscan status
Number at risk
+ive scan 1 
–ive scan 2
Median (months):
Positive scan  9.7 
Negative scan 6.8
Log-rank P-value: 0.33
Positive scan
Negative scan
Hazard ratio negative : positive
5
5 17
7 12
22
22
29
26
33
Figure 2 Survival, by baseline octreotide scintigraphy status. The small
graph shows the hazard ratio of the negative group ( ) compared with the
positive group (þ).
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Pharmacokinetic evaluation was performed on 62, 41, 25, and 7
patients at baseline and after 3, 6, and 9 months of treatment,
respectively. The mean trough plasma concentration at 3 months
was 2205pgml
 1 (range 678–6166pgml
 1). After 6 months, the
mean concentration of plasma octreotide was 3377pgml
 1 (range
956–14290pgml
 1), and after 9 months, 3238pgml
 1 (1307–
9926pgml
 1). Evaluation of those patients who remained on the
study for 6 months or more showed no evidence of accumulation
of octreotide in plasma. Although plasma concentrations fluctu-
ated, they were generally within the range 1000–3000pgml
 1.
Serum AFP was elevated in 50 patients (79%). In four of these it
fell, individually, from 578 to 2, from 1600 to 2, from 48 to 23, and
from 1368 to 56IUml
 1. Serum for chromogranin A estimation
and pharmacokinetics was available from 59 patients (94%), and
tissue was available for IHC analysis of somatostatin receptors
from 20 samples from 19 patients (44%); one patient had two
tumours.
Octreotide scintigraphy
Sixty-one patients had octreotide scans. Table 6 shows the
relationship between the degree of uptake in lesions as assessed
by scintigraphy and the detection of tumour by conventional
imaging. Overall, 34 of 61 patients (56%) had positive scintigrams.
Uptake was clear but faint in the majority of patients. Examples of
octreotide uptake are shown in Figures 3 and 4. In general, the test
was less sensitive than CT scanning in identifying HCC; however, it
provided a noninvasive indication of the presence or absence of
somatostatin receptors. In some instances (Figure 4), the tumour
area showed less uptake than normal liver.
Immunohistochemistry for somatostatin receptors
Positive controls (pancreatic islets, neuroendocrine tumours)
showed clear staining. In the 20 tissue samples that were suitable
for IHC analysis, there were not enough receptors for meaningful
staining with the antiserum SS800, despite considerable efforts to
optimise antibody staining.
Chromogranin A
Figure 5 shows chromogranin A levels. We hypothesised that
patients with high levels might be those with tumours, which
displayed features of neuroendocrine differentiation and therefore
hormone receptors. In turn, these might be those most likely to
respond to therapy with the somatostatin ligand. We therefore
analysed the relationships among chromogranin levels, scintigra-
phy results, and clinical outcomes. There was no clear relationship
between scan positivity and chromogranin A levels. Similarly,
there was no relationship between serum levels of chromogranin A
and survival.
Quality of life
Most patients had adequate English skills to complete the HRQL
forms (47 patients, 75%) and most did so at baseline (46 patients),
but completing the forms decreased over follow-up, as expected.
Fatigue, anxiety, pain, and insomnia were the symptoms rated as
most severe at baseline. After 1 month of treatment, significantly
more patients reported improvements than deteriorations on the
Patient Benefit Form in vomiting, urinary symptoms, constipation,
cough, irritability, and mood (Figure 6). Differences between
ratings of these aspects at baseline and after 1 month, on the Pt
DATA form, were in the same direction as the ratings from the
Patient Benefit Form, but were not statistically significant, and
correlations between the two instruments were modest (Spear-
man’s ro0.3). There were no significant changes in the FACT-Hep
between baseline and 1 month. More detailed analysis of the HRQL
data will be reported elsewhere.
DISCUSSION
The main finding of this study was that octreotide LAR was well
tolerated in patients with advanced HCC – a population with
cirrhosis and chronic liver disease. Although there were few
objective tumour responses (one patient with AFP response plus
partial response on imaging, one patient with AFP response plus
stable disease on imaging), 16 patients (25%) had stable disease or
better for at least 3 months. Forty per cent had only 1–3 injections
of octreotide LAR. It takes about 3 months for steady-state levels to
be built up, so these patients were technically underdosed. The
Table 5 Serious adverse events
Type of event n
Gastrointestinal bleeding 4
Ascites 4
Hepatic encephalopathy 1
Liver failure 1
Dyspnoea 1
Brain metastases 1
Diabetes mellitus 1
Axillary abscess 1
Incarcerated hernia 1
Total 15
Table 6 Octreotide scintigraphy (61 patients) and conventional imaging (CT scanning, 63 patients) compared
Number of patients with the given degree of radioactive
uptake in the tumour at this site
Site
Patients with
disease at this
site confirmed
on CT
Patients with
positive
scintigraphy at
this site
Clear but
faint Moderate Intense
Bone 3 2 1 0 1
Liver 61 32 18 9 5
Lung 3 0 0 0 0
Other 11 4 3 1 0
CT¼computed tomography
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series (CLIP Group, 1998; Kouroumalis et al, 1998; Chow et al,
2002; Dimitroulopoulos et al, 2002; Samonakis et al, 2002; Yuen
et al, 2002). Receptor expression was identified by octreotide
scintigraphy in 34 of 61 patients (56%). There was no clear
relationship between scan positivity and survival. Approximately
A B
D C
Figure 3 (A) Octreotide scintigraphy (4-h image) showing uptake in an HCC in the dome of the right lobe of the liver (arrow): anterior image; (B)
posterior image; normal octreotide uptake in spleen and kidneys; (C) SPECT transaxial section through the upper abdomen showing increased uptake in the
HCC (arrow); and (D) the hepatoma in a corresponding CT scan slice (arrow).
AB
C D
Figure 4 (A) Octreotide scintigraphy (4-h image) showing no evidence of uptake in an HCC in the right lobe of the liver: anterior image; (B) posterior
image; (C) SPECT transaxial section through the upper abdomen showing reduced uptake in the HCC (arrows) compared with normal liver; and (D) the
HCC in a corresponding CT scan slice (arrows).
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while on octreotide.
Unresectable HCC commonly occurs in patients with advanced
chronic liver disease and is difficult to treat. Comorbidities and
poor performance status limit the use of cytotoxic chemotherapy,
so identifying less toxic approaches is important. The small
randomised trial reported by Kouroumalis in 1999 showed an
implausibly large effect of octreotide on survival (Kouroumalis
et al, 1998). It is impossible to tell from this trial whether this effect
on survival was real, and if so, whether it was due to anticancer
effects or other effects such as reduction in portal pressure.
Subsequent studies with long-acting octreotide analogues have
shown less benefit (Raderer et al, 2000; Samonakis et al, 2002) or
no benefit (Yuen et al, 2002). In a recent study, patients selected
for treatment on the basis of scan positivity were treated with
octreotide and, when compared with a control population in a
nonrandomised manner, had better outcomes in terms of survival
and quality of life (Dimitroulopoulos et al, 2002). Nonetheless, this
question will remain open until a definitive confirmatory
randomised trial is performed.
Safety is important for people with comorbidities. There is
limited information available about the elimination kinetics of
octreotide in cirrhosis. Jenkins et al (1998) have demonstrated
prolonged half-life and reduced clearance in patients with cirrhosis
and suggested that dosage regimens should be modified in such
patients to avoid accumulation of the analogue in the blood, which
may result in undesirable side effects or toxicity. Since pharmaco-
kinetics may be altered in patients with cirrhosis, it was
considered necessary to determine whether liver impairment
predisposes to toxicity and whether or not this dose was tolerated
in this patient population. A somewhat reduced dose of
20mgmonth
 1 was arbitrarily selected to evaluate toxicity in this
largely cirrhotic population. At this dose, plasma concentrations
were achieved in the range 1000–3000pgml
 1. These levels are
similar to those typically seen in noncirrhotic patients. For
example, a 30mg i.m. dose resulted in plasma concentrations of
16827174pgml
 1 in a series of six patients with acromegaly
(Stewart et al, 1995). Although sufficient to suppress secretory
function in acromegaly or carcinoid syndrome, it is unclear
whether these concentrations are sufficient for therapeutic impact
in HCC since a dose–response relationship has not been
established for octreotide as an anticancer agent.
Octreotide treatment was well tolerated. The most common side
effects were mild gastrointestinal symptoms and asymptomatic
abnormalities of blood sugar levels. No serious adverse events were
attributed to octreotide.
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Figure 6 Subjective HRQL status reported on the PBF after 1 month of treatment. *Po0.05.
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(Leung and Johnson, 2001). However, a treatment that benefits
only a subset of patients may still be clinically worthwhile.
The very different outcomes in the randomised trials by
Kouroumalis and Yuen probably reflect differences in patient
selection (Kouroumalis et al, 1998; Yuen et al, 2002). The Yuen
study had subjects with more advanced disease, a higher
proportion with viral hepatitis, and a median survival of only
2 months. Our study population was more similar to the
Kouroumalis study population (Table 4) and our median survival
of 8 months lies midway between those of the two arms of the
Kouroumalis study: 13 months in the octreotide arm and 4 months
in the placebo arm.
As HCC can express high-affinity receptors for somatostatin
(Reubi et al, 1999), it was important to determine whether a
relationship existed between the presence of somatostatin recep-
tors and clinical outcomes. We found that octreotide uptake was
highly variable, ranging from less than the uptake of normal liver
to high or intense (Table 6), and this variability was even seen
within an individual (Figure 3). Few patients had intense uptake
(10%), consistent with the observation that receptor numbers in
HCC tend to be lower than those in neuroendocrine tumours
(Reubi et al, 1999). While octreotide scintigraphy was less helpful
than CT scanning for identifying anatomical sites of tumour, its
value may be in providing functional information about these
tumours, particularly evidence of neuroendocrine differentiation.
Confirmation of this using another technique is warranted. As
fresh tissue was not consistently available, it was not possible to
perform radioligand labelling studies to confirm this in vitro or at
a microscopic level. Receptor analysis by IHC was performed on
fixed tissues, but we were not able to reliably detect receptors in
tissue sections. We were therefore unable to show a relationship
between the antibody method and scintigraphy results.
Although HCCs do not typically show neuroendocrine differ-
entiation on histological examination, measurement of serum
chromogranin A levels was undertaken on the basis of a recent
report that levels can be elevated in approximately one-third of
cases (Leone et al, 2002). It was proposed as both a potential
prognostic marker and a marker of neuroendocrine differentia-
tion. In our series, six of 59 patients had levels 10Ul
 1 or less
(reference range 2–8Ul
 1), 35 had levels of 10–50Ul
 1, and 20
had levels higher than 50Ul
 1. Although most patients progressed
on radiological criteria, chromogranin A levels decreased in 15 of
59 patients (25%) and remained stable in 25 (40%), increasing in
a sustained manner in only two patients (3%). We found no
evidence that receptor expression or neuroendocrine features
were associated with either scan positivity or clinical outcomes:
chromogranin A therefore did not appear to be a useful marker for
identifying a subset of tumours more likely to respond, or as a
marker for monitoring clinical progress, with the proviso that the
small sample size did not provide enough statistical power to
detect other than large effects.
Octreotide lowers portal pressure, and is routinely used to treat
patients with variceal bleeding. Since prophylactic octreotide can
prevent bleeding in high-risk patients (Jenkins et al, 1997),
octreotide LAR might reduce morbidity and mortality through
this mechanism. In our trial, gastrointestinal bleeding occurred in
four patients (one peptic ulcer, three varices) with a total follow-up
approaching 4000 patient-months. It is impossible to determine
the effect of octreotide LAR on the rate of complications from
portal hypertension without a randomly allocated control group;
however, the rate in our study seems low compared with other
series (Akanuma et al, 2002).
Although more patients rated improvements than deteriorations
for some symptoms, these ratings were not strongly correlated
with receptor status scores, and it is unclear whether these
represent an effect of treatment. However, the fact that many
patients reported improvements may partly explain the clinical
impression of benefit in some patients. Determining the sig-
nificance and cause of these changes requires a randomly allocated
control group. Our findings support the feasibility and importance
of incorporating measures of HRQL in future trials in advanced
HCC.
This study has shown that octreotide LAR is well tolerated and
may benefit some patients with HCC. We were unable to define,
from octreotide scintigraphy or chromogranin A analyses, a
subgroup more likely to benefit. There was little objective evidence
of antitumour activity. A phase III study is advocated and indeed
warranted given the conflicting findings with previous studies.
However, careful attention should be paid to the selection of the
primary end point and dose selection in the design of such a study.
The potential impact on quality of life, survival, and cirrhosis-
related morbidity, particularly variceal bleeding, justifies the
performance of such a trial.
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